In addition, a phase III study with a total of 756 participants is planned to test the clinical efficiency of combined anti-BTLA and anti-PD1 ICI therapy as adjuvant treatment for early-stage small cell lung cancer after initial radiochemotherapy (NCT06095583). The gene discussed is BTLA; the disease is small cell lung carcinoma.